Chiesi Company Profile

✉ Email this page to a colleague

CHIESI has fifteen approved drugs.

There are forty-eight US patents protecting CHIESI drugs.

There are three hundred and four patent family members on CHIESI drugs in forty-one countries and fifty-three supplementary protection certificates in eighteen countries.

International Patents:	304
US Patents:	48
Tradenames:	16
Ingredients:	10
NDAs:	15
Patent Litigation for Chiesi:	See patent lawsuits for Chiesi

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-002	Dec 21, 2012		RX	Yes	No	9,265,758	⤷ Try a Trial				⤷ Try a Trial
Chiesi	JUXTAPID	lomitapide mesylate	CAPSULE;ORAL	203858-002	Dec 21, 2012		RX	Yes	No	9,861,622	⤷ Try a Trial				⤷ Try a Trial
Chiesi	CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER	nicardipine hydrochloride	INJECTABLE;INTRAVENOUS	019734-002	Jul 31, 2008		RX	Yes	Yes	8,455,524	⤷ Try a Trial				⤷ Try a Trial
Chiesi	MYCAPSSA	octreotide acetate	CAPSULE, DELAYED RELEASE;ORAL	208232-001	Jun 26, 2020		RX	Yes	Yes	8,535,695	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chiesi	ZYFLO CR	zileuton	TABLET, EXTENDED RELEASE;ORAL	022052-001	May 30, 2007	5,422,123	⤷ Try a Trial
Chiesi	CARDENE SR	nicardipine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020005-002	Feb 21, 1992	3,985,758	⤷ Try a Trial
Chiesi	CARDENE SR	nicardipine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020005-002	Feb 21, 1992	5,198,226	⤷ Try a Trial
Chiesi	ZYFLO CR	zileuton	TABLET, EXTENDED RELEASE;ORAL	022052-001	May 30, 2007	6,183,778	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	0.1 mg/mL, 200 mL and0.2mg/mL, 200 mL	➤ Subscribe	2013-06-20
➤ Subscribe	Tablets	500 mg	➤ Subscribe	2016-01-29
➤ Subscribe	Injection	2.5 mg/mL, 10 mL Ampoules	➤ Subscribe	2006-12-27
➤ Subscribe	Inhalation Solution	300 mg/4 mL	➤ Subscribe	2017-08-31

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1725234	2013/063	Ireland	⤷ Try a Trial	PRODUCT NAME: LOMITAPIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/13/851/001-003 20130731
1725234	2014C/002	Belgium	⤷ Try a Trial	PRODUCT NAME: LOMITAPIDE ET TOUTE FORME THERAPEUTIQUEMENT EQUIVALENTE TELLE QUE PROTEGEE PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/13/851/001 20130805
1280520	CA 2015 00017	Denmark	⤷ Try a Trial	PRODUCT NAME: TOBRAMYCIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/10/652/001-003 20110720
1725234	C20140001 00107	Estonia	⤷ Try a Trial	PRODUCT NAME: LOMITAPIID;REG NO/DATE: K(2013)5153(LOPLIK) 05.08.2013
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.